Emerging life science company Proteomics International Laboratories (ASX:PIQ) (PILL) has appointed John (Chuck) Morrison as the company’s Head of Global Business Development.
Morrison has more than 36 years’ experience in the life sciences, biotechnology and diagnostic industries and his appointment represents a key addition to PILL’s senior management team.
Diagnostics are a key component of the company’s operations.
Morrison will play a key role in sourcing and executing commercialisation opportunities for products derived from the company’s proprietary proteomics-based technology platform.
The U.S. market is a significant focus for PILL, as it is a major growth market for key proteomics applications, such as in medicine, and developing innovation to apply the technology in the market.
PILL is well funded with over $3 million in cash, after listing on the ASX in April 2015.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.